Maximum quantity allowed is 999
请选择数量
CAS RN: 154361-50-9 | 產品號碼: C2878
| 產品號碼 | C2878 |
純度/分析方法 
|
>98.0%(T)(HPLC) |
| 分子式 / 分子量 | C__1__5H__2__2FN__3O__6 = 359.35 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件
|
Refrigerated (0-10°C) |
| 應避免的情況 | Heat Sensitive |
| 包裝和容器
|
1G-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 154361-50-9 |
| Reaxys-RN | 8583270 |
| PubChem Substance ID | 253661933 |
| Merck Index(14) | 1754 |
| MDL編號 | MFCD00930626 |
產品規格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Specific rotation [a]20/D | +96.0 to +100.0 deg(C=1, MeOH) |
性質
| 熔點 | 123 °C(dec.) |
| 比旋光 [α]D | 98° (C=1,MeOH) |
| 水溶性 | Slightly soluble |
| Degree of solubility in water | 26 g/l 20 °C |
GHS
| 圖形表示 |
|
| 信號詞 | Danger |
| 危險性說明 | H315 : Causes skin irritation. H319 : Causes serious eye irritation. H360 : May damage fertility or the unborn child. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. P405 : Store locked up. |
相關法規
| RTECS # | HA3852500 |
運輸資料
| HS編碼* | 2934.99-000 |
Application
Capecitabine: A Prodrug of 5-fluorouracil (5-FU) [F0151] for Selective Delivery to Tumor
Capecitabine is a prodrug of antitumor antimetabolite, metabolized to the active form 5-fluorouracil (5-FU) [F0151] by three enzymes located in the liver and in tumors. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5'-deoxy-5-fluorocytidine [D4342] and 5'-deoxy-5-fluorouridine (doxifluridine) [D3579], to form 5-FU. Capecitabine and its intermediary metabolites are not cytotoxic by themselves. The final step (doxifluridine to 5-FU) requires thymidine phosphorylase (dThdPase) that is significantly more active in tumor than normal tissue. This tumor-selective delivery of 5-FU ensured greater efficacy and a more favorable safety profile than with other fluoropyrimidines. For your reference, [D5787] is a synthetic precursor of capecitabine. (The product is for research purpose only.)
References
- Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue
- Capecitabine: preclinical pharmacology studies (a review)
- Clinical pharmacokinetics of capecitabine (a review)
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer
- Capecitabine: an overview of the side effects and their management (a review)
考研文獻
文檔
產品介紹報導
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。